行为治疗对阿尔茨海默病患者激越症状使用精神药物无长期影响。
No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients.
作者信息
Weiner Myron F, Tractenberg Rochelle E, Sano Mary, Logsdon Rebecca, Teri Linda, Galasko Douglas, Gamst Anthony, Thomas Ron, Thal Leon J
机构信息
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, USA.
出版信息
J Geriatr Psychiatry Neurol. 2002 Summer;15(2):95-8. doi: 10.1177/089198870201500208.
Th determine if teaching caregivers behavior management techniques (BMTs) reduces long-term psychotropic use in Alzheimer's disease (AD) patients, we examined 12-month follow-up data from a 4-month randomized study comparing placebo, BMTs, trazodone, and haloperidol for the treatment of agitated behaviors in persons with AD. After 4 months, treatment was allowed with any agent. Between 42.8% and 51% of AD patients received additional psychotropics between 4 and 12 months. The relative risk of being prescribed any psychotropic drug after the 4-month trial was at or about 1.0 for subjects in each drug arm or placebo arm versus BMTs. We concluded that teaching caregivers BMTs did not diminish long-term prescription of psychotropic drugs.
为了确定教导护理人员行为管理技术（BMTs）是否能减少阿尔茨海默病（AD）患者长期使用精神药物的情况，我们研究了一项为期4个月的随机研究的12个月随访数据，该研究比较了安慰剂、BMTs、曲唑酮和氟哌啶醇对AD患者激越行为的治疗效果。4个月后，允许使用任何药物进行治疗。在4至12个月期间，42.8%至51%的AD患者接受了额外的精神药物治疗。与BMTs相比，在4个月试验后，每个药物组或安慰剂组的受试者被开具任何精神药物的相对风险为1.0或约为1.0。我们得出结论，教导护理人员BMTs并不能减少精神药物的长期处方。
Zotero 插件